Literature DB >> 33633691

Role of Sphingosine Kinase in Type 2 Diabetes Mellitus.

Yanfei Qi1, Wei Wang2, Ziyu Song2, Gulibositan Aji2, Xin Tracy Liu1, Pu Xia2.   

Abstract

Sphingolipids are a class of essential lipids, functioning as both cell membrane constituents and signaling messengers. In the sphingolipid metabolic network, ceramides serve as the central hub that is hydrolyzed to sphingosine, followed by phosphorylation to sphingosine 1-phosphate (S1P) by sphingosine kinase (SphK). SphK is regarded as a "switch" of the sphingolipid rheostat, as it catalyzes the conversion of ceramide/sphingosine to S1P, which often exhibit opposing biological roles in the cell. Besides, SphK is an important signaling enzyme that has been implicated in the regulation of a wide variety of biological functions. In recent years, an increasing body of evidence has suggested a critical role of SphK in type 2 diabetes mellitus (T2D), although a certain level of controversy remains. Herein, we review recent findings related to SphK in the field of T2D research with a focus on peripheral insulin resistance and pancreatic β-cell failure. It is expected that a comprehensive understanding of the role of SphK and the associated sphingolipids in T2D will help to identify druggable targets for future anti-diabetes therapy.
Copyright © 2021 Qi, Wang, Song, Aji, Liu and Xia.

Entities:  

Keywords:  ceramide; insulin resistance; sphingolipid; sphingosine 1-phosphate; β-cell

Mesh:

Substances:

Year:  2021        PMID: 33633691      PMCID: PMC7899982          DOI: 10.3389/fendo.2020.627076

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  130 in total

1.  Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate.

Authors:  O Cuvillier; G Pirianov; B Kleuser; P G Vanek; O A Coso; S Gutkind; S Spiegel
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

2.  Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility.

Authors:  J P Hobson; H M Rosenfeldt; L S Barak; A Olivera; S Poulton; M G Caron; S Milstien; S Spiegel
Journal:  Science       Date:  2001-03-02       Impact factor: 47.728

3.  Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in PKC-theta localization.

Authors:  K S Bell; C Schmitz-Peiffer; M Lim-Fraser; T J Biden; G J Cooney; E W Kraegen
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-11       Impact factor: 4.310

4.  Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice.

Authors:  M M Ma; J L Chen; G G Wang; H Wang; Y Lu; J F Li; J Yi; Y J Yuan; Q W Zhang; J Mi; L Sh Wang; H F Duan; C T Wu
Journal:  Diabetologia       Date:  2007-01-31       Impact factor: 10.122

5.  Molecular cloning and functional characterization of murine sphingosine kinase.

Authors:  T Kohama; A Olivera; L Edsall; M M Nagiec; R Dickson; S Spiegel
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

6.  Sphk2-/- mice are protected from obesity and insulin resistance.

Authors:  Shwetha Ravichandran; Brian S Finlin; Philip A Kern; Sabire Özcan
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-12-26       Impact factor: 5.187

7.  A lipid binding domain in sphingosine kinase 2.

Authors:  Anthony S Don; Hugh Rosen
Journal:  Biochem Biophys Res Commun       Date:  2009-01-23       Impact factor: 3.575

8.  Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression.

Authors:  Yosuke Osawa; Ekihiro Seki; Yuzo Kodama; Atsushi Suetsugu; Kouichi Miura; Masayuki Adachi; Hiroyasu Ito; Yoshimune Shiratori; Yoshiko Banno; Jerrold M Olefsky; Masahito Nagaki; Hisataka Moriwaki; David A Brenner; Mitsuru Seishima
Journal:  FASEB J       Date:  2010-12-16       Impact factor: 5.191

9.  Adipocyte lipolysis-stimulated interleukin-6 production requires sphingosine kinase 1 activity.

Authors:  Wenliang Zhang; Emilio P Mottillo; Jiawei Zhao; Allison Gartung; Garrett C VanHecke; Jen-Fu Lee; Krishna R Maddipati; Haiyan Xu; Young-Hoon Ahn; Richard L Proia; James G Granneman; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2014-09-24       Impact factor: 5.486

10.  Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation.

Authors:  Kazuhiro Ishimaru; Kazuaki Yoshioka; Kuniyuki Kano; Makoto Kurano; Daisuke Saigusa; Junken Aoki; Yutaka Yatomi; Noriko Takuwa; Yasuo Okamoto; Richard L Proia; Yoh Takuwa
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

View more
  5 in total

1.  Influence of type 2 diabetes microangiopathy on bone mineral density and bone metabolism: A meta-analysis.

Authors:  Jinlong Zhao; Guihong Liang; Miaohui Luo; Weiyi Yang; Nanjun Xu; Minghui Luo; Jianke Pan; Jun Liu; Lingfeng Zeng
Journal:  Heliyon       Date:  2022-10-08

2.  Upregulated lncRNA HCG18 in Patients with Non-Alcoholic Fatty Liver Disease and Its Regulatory Effect on Insulin Resistance.

Authors:  Yu Xia; Yanxia Zhang; Huiyun Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-12-03       Impact factor: 3.168

Review 3.  Targeting Chronic Inflammation of the Digestive System in Cancer Prevention: Modulators of the Bioactive Sphingolipid Sphingosine-1-Phosphate Pathway.

Authors:  Eileen M McGowan; Yiguang Lin; Size Chen
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

Review 4.  Ceramide Transfer Protein (CERT): An Overlooked Molecular Player in Cancer.

Authors:  Long Hoa Chung; Da Liu; Xin Tracy Liu; Yanfei Qi
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

Review 5.  Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases.

Authors:  Derek Strassheim; Timothy Sullivan; David C Irwin; Evgenia Gerasimovskaya; Tim Lahm; Dwight J Klemm; Edward C Dempsey; Kurt R Stenmark; Vijaya Karoor
Journal:  Cells       Date:  2021-11-29       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.